Jessica Fye
Stock Analyst at JP Morgan
(4.42)
# 286
Out of 5,182 analysts
216
Total ratings
61.03%
Success rate
14.54%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKTS Aktis Oncology | Initiates: Overweight | $30 | $18.60 | +61.29% | 1 | Feb 3, 2026 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $24 → $26 | $20.06 | +29.61% | 6 | Nov 4, 2025 | |
| STOK Stoke Therapeutics | Maintains: Neutral | $15 → $25 | $33.33 | -24.99% | 5 | Nov 3, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $25 → $23 | $12.12 | +89.77% | 5 | Oct 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $204 → $199 | $203.98 | -2.44% | 5 | Oct 27, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $63 → $65 | $63.86 | +1.79% | 15 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Underweight | $26 → $25 | $47.14 | -46.97% | 14 | Oct 23, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $121 → $120 | $102.06 | +17.58% | 14 | Oct 23, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $475 → $473 | $302.11 | +56.57% | 9 | Oct 13, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $78 → $76 | $23.56 | +222.58% | 4 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $89 | $97.74 | -8.94% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $119 | $53.30 | +123.26% | 5 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $264 | $222.08 | +18.88% | 16 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $517 → $530 | $430.14 | +23.22% | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $345 → $385 | $298.16 | +29.13% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $49 → $80 | $71.78 | +11.45% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $38.15 | +36.30% | 6 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $77 | $94.06 | -18.14% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $35 | $34.14 | +2.52% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $111 → $135 | $134.94 | +0.04% | 9 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $569.11 | -42.01% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $8.86 | +46.73% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $28.79 | +73.67% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $29.04 | +3.31% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $83.81 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $8.23 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $1.91 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $13.96 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.84 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.66 | +321.69% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.92 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $13.75 | - | 1 | Feb 8, 2018 |
Aktis Oncology
Feb 3, 2026
Initiates: Overweight
Price Target: $30
Current: $18.60
Upside: +61.29%
Denali Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $20.06
Upside: +29.61%
Stoke Therapeutics
Nov 3, 2025
Maintains: Neutral
Price Target: $15 → $25
Current: $33.33
Upside: -24.99%
NovoCure
Oct 27, 2025
Maintains: Neutral
Price Target: $25 → $23
Current: $12.12
Upside: +89.77%
Jazz Pharmaceuticals
Oct 27, 2025
Maintains: Overweight
Price Target: $204 → $199
Current: $203.98
Upside: -2.44%
Halozyme Therapeutics
Oct 27, 2025
Maintains: Neutral
Price Target: $63 → $65
Current: $63.86
Upside: +1.79%
Moderna
Oct 23, 2025
Maintains: Underweight
Price Target: $26 → $25
Current: $47.14
Upside: -46.97%
BioNTech SE
Oct 23, 2025
Maintains: Neutral
Price Target: $121 → $120
Current: $102.06
Upside: +17.58%
Alnylam Pharmaceuticals
Oct 13, 2025
Maintains: Overweight
Price Target: $475 → $473
Current: $302.11
Upside: +56.57%
Legend Biotech
Oct 9, 2025
Maintains: Overweight
Price Target: $78 → $76
Current: $23.56
Upside: +222.58%
Oct 9, 2025
Maintains: Neutral
Price Target: $73 → $89
Current: $97.74
Upside: -8.94%
Oct 9, 2025
Maintains: Overweight
Price Target: $116 → $119
Current: $53.30
Upside: +123.26%
Oct 9, 2025
Maintains: Overweight
Price Target: $260 → $264
Current: $222.08
Upside: +18.88%
Oct 8, 2025
Maintains: Overweight
Price Target: $517 → $530
Current: $430.14
Upside: +23.22%
Oct 8, 2025
Maintains: Overweight
Price Target: $345 → $385
Current: $298.16
Upside: +29.13%
Oct 8, 2025
Upgrades: Overweight
Price Target: $49 → $80
Current: $71.78
Upside: +11.45%
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $38.15
Upside: +36.30%
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $94.06
Upside: -18.14%
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $34.14
Upside: +2.52%
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $134.94
Upside: +0.04%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $569.11
Upside: -42.01%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $8.86
Upside: +46.73%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $28.79
Upside: +73.67%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $29.04
Upside: +3.31%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $83.81
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $8.23
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $1.91
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $13.96
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $0.84
Upside: -
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.66
Upside: +321.69%
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $7.92
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $13.75
Upside: -